Albumin-bound paclitaxel takes the advantage of nanotechnology to combine the drug substance with human albumin to generate nanoparticles with improved solubility
Albumin-bound paclitaxel(Apexelsin) takes the advantage of nanotechnology to combine the drug substance with human albumin to generate nanoparticles with improved solubility, featured by "Three Highs and One Low", i.e. high dose, high distribution in tumor tissue, high efficacy, and low toxicity. Albumin-bound paclitaxel is recommended by the NCCN and CSCO guidelines for the treatment of breast cancer. It is the only product in China that is applied simultaneously in China, the United States, and the European Union and the NDA in China and European Union has been accepted for review.
Indications
Albumin-bound paclitaxel monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline-containing therapy is not indicated.
Albumin-bound paclitaxel in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.
Albumin-bound paclitaxel in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.
Strength
100mg/vial
Recommended reading
Unlocking the Power of Albumin-Bound Paclitaxel: Quality, Affordability, and Innovation
Exploring the Power of Albumin-Bound Paclitaxel: A Breakthrough in Cancer Treatment
Download instructions
Contact us